25B-NBOMe ( NBOMe-2C-B , Cimbi-36 , Nova , BOM 2-CB ) is a psychoactive substance from the phenylethylamine class, derived from 2C-B , developed in 2004 by Ralph Heim at the Free University of Berlin . It acts as a potent partial agonist of the human 5-HT 2A receptor . [1] [2] [3] [4] Unsystematic consumer reports suggest that 25B-NBOMe is an active hallucinogen at a dose of only 250-500 mcg, which makes it similar in potency to other hallucinogens derived from phenylethylamine, such as Bromo-DragonFLY . The duration of the effect lasts about 12-16 hours.
| 25B-NBOMe | |
|---|---|
 | |
| Are common | |
| Systematic name | 2- (4-bromo-2,5-dimethoxyphenyl) -N - [(2-methoxyphenyl) methyl] ethanamine |
| Chem. formula | C 18 H 22 BrNO 3 |
| Physical properties | |
| Molar mass | 380.275 g / mol |
| Classification | |
| Reg. CAS number | |
| PubChem | |
| Smiles | |
| Inchi | |
| ChemSpider | |
Content
Use as a radioactive indicator
A labeled carbon-11 variant of this compound ([ 11 C] Cimbi-36) was synthesized and confirmed as a radioactive indicator for positron emission tomography ( PET ) in Copenhagen. [5] [6] [7] As a 5-HT 2A receptor agonist, the PET radioligand [ 11 C] Cimbi-36 suggested that it provides a more functional marker for these receptors. In addition, [ 11 C] Cimbi-36 is being investigated as a potential marker for serotonin excretion and, thus, can serve as an indicator of serotonin levels in vivo. [ 11 C] Cimbi-36 is currently undergoing clinical trials as a PET ligand in humans.
Toxicity
25B-NBOMe is used in clinical trials with an estimated dose to ensure safety in humans with only 1 mcg. Such a dose is only 1 / 300th of the dose, which is expected to be hallucinogenic to humans, and recreational use is expected to significantly exceed doses that are believed to be safe for humans. [8] One case is reported when 25B-NBOMe was identified as the cause of death for a 17-year-old boy. [9] Several deaths were attributed to its close counterpart, 25I-NBOMe.
Legal Status
Canada
As of October 31, 2016; 25B-NBOMe is a controlled substance (List III) in Canada. [ten]
Russia
Prohibited as a derivative of 2-amino-1- (4-bromo-2,5-dimethoxyphenyl) ethanone by a regulation of May 5, 2015. [eleven]
USA
In November 2013, the UBN temporarily placed 25B-NBOMe (along with 25I-NBOMe and 25C-NBOMe ) on Schedule I of the Controlled Substances Act, which makes it an illegal substance for two years. [12] In November 2015, the temporary placement was extended for another year. [13]
See also
- 2C-C-NBOMe
- 2C-B
- 2C-I
Notes
- ↑ Ralf Heim. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (German) . diss.fu-berlin.de (28. Februar 2010). Date of treatment May 10, 2013.
- ↑ Maria Silva PhD. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Universität Regensburg, 2009.
- ↑ Silva ME, Heim R., Strasser A., Elz S., Dove S. Theoretical studies on the interaction of partial agonists with the 5-HT (2A) receptor (Eng.) // Journal of Computer-aided Molecular Design: journal. - 2011 .-- January ( vol. 25 , no. 1 ). - P. 51-66 . - DOI : 10.1007 / s10822-010-9400-2 . - PMID 21088982 .
- ↑ Hansen, M .; Phonekeo, K .; Paine, JS; Leth-Petersen, S .; Begtrup, M .; Bräuner-Osborne, H .; Kristensen, JL Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT 2A / 2C Agonists (Eng.) // ACS Chemical Neuroscience : journal. - 2014 .-- Vol. 5 , no. 3 . - P. 243-249 . - DOI : 10.1021 / cn400216u . - PMID 24397362 .
- ↑ Hansen, M. (2011). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. Archived October 22, 2013 at Wayback Machine PhD Thesis, University of Copenhagen.
- ↑ Ettrup, A .; Hansen, M .; Santini, MA; Paine, J .; Gillings, N .; Palner, M .; Lehel, S .; Herth, MM; Madsen, J .; Kristensen, J .; Begtrup, M .; Knudsen, GM Radiosynthesis and in vivo evaluation of a series of substituted 11 C-phenethylamines as 5-HT 2A agonist PET tracers (English) // European Journal of Nuclear Medicine and Molecular Imaging : journal. - 2010 .-- Vol. 38 , no. 4 . - P. 681-693 . - DOI : 10.1007 / s00259-010-1686-8 . - PMID 21174090 .
- ↑ Ettrup, A .; Holm, SR; Hansen, M .; Wasim, M .; Santini, MA; Palner, M .; Madsen, J .; Svarer, C .; Kristensen, JL; Knudsen, GM Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand \ 11C] Cimbi-36 (Eng.) // Molecular Imaging and Biology : journal. - 2013 .-- Vol. 15 , no. 4 . - P. 376-383 . - DOI : 10.1007 / s11307-012-0609-4 . - PMID 23306971 .
- ↑ Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C] Cimbi-36 (link not available)
- ↑ Roxas, Gabriel . Designer Drug Identified As Cause Of Plano Teen's Death (February 19, 2015).
- ↑ Canada Gazette - Regulations Amending the Food and Drug Regulations (Part J - 2C-phenethylamines)
- ↑ Resolution of the Government of the Russian Federation of 06.06.1998 N 681 "On approval of the list of narcotic drugs, psychotropic substances and their precursors to be controlled in the Russian Federation ...
- ↑ Three More Synthetic Drugs Become Illegal For At Least Two Years
- ↑ Drug Enforcement Administration. Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order (Eng.) // Fed Regist. : journal. - 2015. - Vol. 80 , no. 219 . - P. 70657-70659 . - PMID 26567439 .